Nivolumab Plus Ipilimumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma
J Thorac Oncol
.
2022 Jan;17(1):30-33.
doi: 10.1016/j.jtho.2021.07.029.
Author
Paul Baas
1
Affiliation
1
Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: p.baas@nki.nl.
PMID:
34930609
DOI:
10.1016/j.jtho.2021.07.029
No abstract available
Publication types
Editorial
MeSH terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Ipilimumab / therapeutic use
Lung Neoplasms* / drug therapy
Mesothelioma, Malignant*
Nivolumab / therapeutic use
Standard of Care
Substances
Ipilimumab
Nivolumab